AEDs Flashcards
Agents that enhance VGSC inactivation
Phenytoin
Carbamazepine
Lamotrigine
Phenytoin metabolism
Metabolism by CYP2C9, 2C19
Potent inducer of CYP and UGT-glucuronidation
95% protein bound
Phenytoin adverse effects
Hirsutism
Osteomalacia
Teratogenic
Megaloblastic anaemia
Arrhythmia
Insulin inhibited
Lymphadenopathy
Ataxia
Neuropathy/Nystagmus
Diplopia
SJS/TEN
Lupus syndrome
Agranulocytosis/aplastic anaemia
Gum hyperplasia
Hepatotoxicity
Carbamazepine metabolism
Metabolism by CYP3A4
Potent CYP inducer
Carbamazepine adverse effects
Dizziness, ataxia
Headache, drowsiness
Diplopia, blurred vision
Mild generalised rash
Leukopenia
Agranulocytosis
SIADH
Lamotrigine metabolism
Metabolism by UGT-glucuronidation
Lamotrigine adverse effects
Maculo-papular rash
SJS/TEN/DRESS
Hypersensitivity
Diplopia/blurred vision
Photosensitivity
Tremor
Agitation
Nausea/vomiting
Aplastic anaemia
HLA associated with Carbamazepine induced SJS
HLA 1502
Ethosuximide MOA
T-type Ca channel blocker
Ethosuximide adverse effects
Fatigue
GI upset
Headache
Itch
SJS
Ethosuximide metabolism
CYP3A4
Keppra mechanism of action
Binds to neuronal synaptic vesicle glycoprotein 2A
Keppra adverse efects
Depression, agitation
Diarrhoea/vomiting
Dyspepsia
Drowsiness
Diplopia
Dyscrasias
DRESS/SJS/TEN
Psychosis
Sodium valproate MOA
Increases GABA levels
Blocks VGSCs and VGCCs
Sodium valproate pharmacology
CYP metabolism
Mostly protein bound